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SResults: Indications for CTO-PCI were mainly: angina in 52.8% of cases, acute coro-
nary syndromes in 13.2%, dyspnea in 3,6%, and silent ischemia in 29.6% (397 cases).
Clinical follow-up was obtained in 92.5% of cases at a mean of 50.228.9 months.
Patients with silent ischemia were older (64.011.8 vs. 62.710.2 years, p¼0.037) and
more frequently diabetics (33.2 vs. 24.9%, p¼0,001). Procedural success rate was
similar (74.6 vs. 74.4%, p¼ns, respectively) as well as all-causes mortality at follow up
(Silent ischemia 10.7 vs. sympt 12.5%, p¼ns) and cardiac death (6.1 vs. 7.4%, p¼ns).
However, patient oriented major adverse cardiovascular and cerebrovascular events
(MACCE) were lower in asymptomatic patients (17.4 vs. 22.7%, p¼0,033), mainly due
to a lower rate of TVR (9.3 vs. 13.3%, p¼0,034) at follow-up.
Conclusions: Our study shows that CTO PCI in patients with silent ischemia is a safe
procedure in experienced hands and that procedural success is a predictor of improved
outcome in this subgroup of patients. Same efforts should be made to offer CTO
recanalization to asymptomatic patients in the presence of ischemia as in symptomatic
patients.
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Background: In this study, we sought to compare the clinical outcomes in patients
undergoing percutaneous coronary interventions (PCI) with transfemoral access using
bivalirudin versus transradial access using heparin or low molecular weight heparin
(LMWH). Recent trend towards transradial PCI is putting pressure on older physicians
to use transradial access. Data suggests that the use of bivalirudin is superior to
heparin when analyzing overall outcomes in coronary PCI via transfemoral approach.
There is a paucity of data when comparing use of bivalirudin in transfemoral coronary
PCI versus transradial coronary PCI with heparin/LMWH.
Methods: 631 patients at a high volume university medical center undergoing coro-
nary PCI were retrospectively divided into two groups (femoral artery access with
bivalirudin and radial artery access with heparin/LMWH). Cardiology fellows ob-
tained access in greater than 90% of all patients.
Results: All-cause mortality, vascular complications, bleeding events within 72 hours,
and transfusion rates were not statistically signiﬁcant between the two groups.One-year ischemic outcomes according to coronary calciﬁcation severity
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MACE 32.0% (33) 22.6% (56) 20.8% (83) 0.059 0.07 0.02 0.55
Death 11.8% (12) 3.7% (9) 4.5% (18) 0.006 0.004 0.007 0.58
Cardiac death 5.9% (6) 2.8% (7) 3.7% (15) 0.39 0.17 0.35 0.52
Non-cardiac death 6.3% (6) 0.8% (2) 0.8% (3) 0.0002 0.003 0.0004 0.95
Death/MI 31.1% (32) 19.7% (49) 16.4% (66) 0.006 0.03 0.001 0.28
Myocardial infarction 22.5% (23) 16.5% (41) 13.8% (55) 0.10 0.22 0.03 0.31
Unplanned
revascularization
1.1% (1) 4.3% (10) 5.8% (22) 0.14 0.16 0.06 0.39
Value are presented as % (n),
MACE¼major adverse cardiac event; MI¼myocardial infarctionConclusions: In this single center study, transradial coronary PCI using heparin or
LMWH has no advantage over transfemoral coronary PCI using bivalirudin in terms
of overall mortality and bleeding outcomes. Further studies to evaluate transradial
coronary PCI using Bivairudin are warranted.
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Background: Treatment of drug-eluting stent in-stent restenosis (DES-ISR) is still
challenging with no established best strategy. The intention of PEPCAD China ISR
was to demonstrate the efﬁcacy of paclitaxel-coated balloon (PCB) angioplasty in
a non-European patient population with DES-ISR.
Methods: PEPCAD China ISR was a 220 patient randomized (1:1), single blind
prospective multicenter trial conducted in China. Patients with DES-ISR receivedB18 JACC Vol 62/18/Suppl B j October 27–Novembeeither PCB (SeQuent Please, B.Braun Melsungen AG, Germany) or paclitaxel-
eluting stent (PES, Taxus Liberté, Boston Scientiﬁc, Natick, MA, USA) treat-
ment. The primary endpoint was in-segment late lumen loss at 9 months.
Secondary endpoints included 9-month % diameter stenosis (DS), binary restenosis
rate, and 12-month target lesion failure (TLF) deﬁned as the composite of cardiac
death, target vessel myocardial infarction or ischemia-driven target lesion revas-
cularization. In addition, deﬁnite/probable stent thrombosis (ST) rates were
documented.
Results: There were no signiﬁcant baseline differences between both treatment groups
in terms of patient, lesion or procedural characteristics. At 9 months, in-segment late
lumen loss in the PCB group was non-inferior to the PES group (0.460.51 mm vs.
0.550.61 mm, difference: -0.06 mm with 95%CI: [-0.23, 0.10], p for non-
inferiority¼0.0005). The 9-month in-segment %DS, binary restenosis, 12-month TLF,
and deﬁnite/probable ST rates were no statistical differences between both treatment
groups (29.0  21.3 vs. 30.8  25.3, p¼0.59; 18.6% vs. 23.8%, p¼0.39; 16.5% vs.
16.0%, p¼0.92; 0.9% vs. 1.0%, p¼1.00, respectively).
Conclusions: In a randomized trial of 220 patients, angioplasty with a PCB was non-
inferior to PES implantation when used to treat DES-ISR. Based upon these as well as
prior randomized trial data, PCB angioplasty offers an effective treatment for DES-
ISR without the necessity of implanting additional metal layers for drug release
(ClinicalTrials.gov identiﬁer: NCT 01622075).
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Background: The treatment of calciﬁed coronary lesions by percutaneous
coronary intervention (PCI) has been shown to be associated with poor
outcomes and an increased rate of complications. However, the impact of
coronary calciﬁcation in patients undergoing coronary artery bypass grafting
(CABG) is unknown.
Methods: Following coronary angiography, CABG was performed in 755 patients
presenting with an acute coronary syndrome (ACS) in the ACUITY trial. Patients
were divided in 3 groups (severe, moderate, none/mild) according to the presence and
extent of calciﬁed coronary lesions as assessed by an independent angiographic core
laboratory. Major ischemic outcomes were assessed at 1 year.
Results: One of more severely calciﬁed lesions was present in 103 (13.6%) patients,
moderate calciﬁcation was present in 249 (33.0%) patients and no/mild calciﬁcation
was present in 403 (53.4%) patients. Patients with severely calciﬁed lesions were more
likely to be older, have lower weight, be smokers, have hypertension and renal
insufﬁciency at baseline. Angiographically, they were more likely to have more
lesions and higher TIMI risk score. There were no differences between groups in the
rates of multivessel disease or number or type (arterial vs. venous) of grafts performed.
The presence of severe calciﬁcation compared to moderate or none/mild was asso-
ciated with a signiﬁcant higher unadjusted rate of death (11.8% vs. 3.7% vs. 4.5%,
p¼0.006), death/MI (31.1% vs. 19.7% vs. 16.4%, p¼0,006) and MACE (32.0% vs.
22.6% vs. 20.8%, p¼0.059) at 1 year. By multivariable analysis, the presence of
severe lesion calciﬁcation was identiﬁed as an independent predictor of 1-year death/
MI (HR 1.77 [95% CI 1.18, 2.66], p¼0.006) and MACE (HR 1.49 [95% CI 1.01,
2.21], p¼0.04).
Conclusions: The presence of severely calciﬁed coronary lesions was associated with
signiﬁcantly worse ischemic outcomes after CABG in patients with ACS.r 1, 2013 j TCT Abstracts/ORAL/Miscellaneous Coronary Intervention
